Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline
Chronic hepatitis C virus (HCV) infection increases all-cause mortality, rates of cirrhosis, hepatocellular carcinoma, liver transplantation and overall health care utilization. Morbidity and mortality disproportionately affect individuals born between 1945 and 1975. The recent development of well-t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2014/109046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567947276582912 |
|---|---|
| author | Daniel J Smyth Duncan Webster Lisa Barrett Mark MacMillan Lisa McKnight Frank Schweiger |
| author_facet | Daniel J Smyth Duncan Webster Lisa Barrett Mark MacMillan Lisa McKnight Frank Schweiger |
| author_sort | Daniel J Smyth |
| collection | DOAJ |
| description | Chronic hepatitis C virus (HCV) infection increases all-cause mortality, rates of cirrhosis, hepatocellular carcinoma, liver transplantation and overall health care utilization. Morbidity and mortality disproportionately affect individuals born between 1945 and 1975. The recent development of well-tolerated and highly effective therapies for chronic HCV infection represents a unique opportunity to dramatically reduce rates of HCV-related complications and their costs. Critical to the introduction of such therapies will be well-designed provincial programming to ensure immediate treatment access to individuals at highest risk for complication, and well-defined strategies to address the global treatment needs of traditionally high-risk and marginalized populations. HCV practitioners in New Brunswick created a provincial strategy that stratifies treatment according to those at highest need, measures clinical impact, and creates evaluation strategies to demonstrate the significant direct and indirect cost savings anticipated with curative treatments. |
| format | Article |
| id | doaj-art-85145a9ba75840d9911e595a8493e379 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-85145a9ba75840d9911e595a8493e3792025-02-03T01:00:10ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972014-01-01281052953410.1155/2014/109046Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation GuidelineDaniel J Smyth0Duncan Webster1Lisa Barrett2Mark MacMillan3Lisa McKnight4Frank Schweiger5Horizon Health Network, New Brunswick, CanadaHorizon Health Network, New Brunswick, CanadaCapital Health, Halifax, Nova Scotia, CanadaHorizon Health Network, New Brunswick, CanadaHorizon Health Network, New Brunswick, CanadaHorizon Health Network, New Brunswick, CanadaChronic hepatitis C virus (HCV) infection increases all-cause mortality, rates of cirrhosis, hepatocellular carcinoma, liver transplantation and overall health care utilization. Morbidity and mortality disproportionately affect individuals born between 1945 and 1975. The recent development of well-tolerated and highly effective therapies for chronic HCV infection represents a unique opportunity to dramatically reduce rates of HCV-related complications and their costs. Critical to the introduction of such therapies will be well-designed provincial programming to ensure immediate treatment access to individuals at highest risk for complication, and well-defined strategies to address the global treatment needs of traditionally high-risk and marginalized populations. HCV practitioners in New Brunswick created a provincial strategy that stratifies treatment according to those at highest need, measures clinical impact, and creates evaluation strategies to demonstrate the significant direct and indirect cost savings anticipated with curative treatments.http://dx.doi.org/10.1155/2014/109046 |
| spellingShingle | Daniel J Smyth Duncan Webster Lisa Barrett Mark MacMillan Lisa McKnight Frank Schweiger Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline Canadian Journal of Gastroenterology and Hepatology |
| title | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline |
| title_full | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline |
| title_fullStr | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline |
| title_full_unstemmed | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline |
| title_short | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline |
| title_sort | transitioning to highly effective therapies for the treatment of chronic hepatitis c virus infection a policy statement and implementation guideline |
| url | http://dx.doi.org/10.1155/2014/109046 |
| work_keys_str_mv | AT danieljsmyth transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline AT duncanwebster transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline AT lisabarrett transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline AT markmacmillan transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline AT lisamcknight transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline AT frankschweiger transitioningtohighlyeffectivetherapiesforthetreatmentofchronichepatitiscvirusinfectionapolicystatementandimplementationguideline |